Hypera (HYPE3) Q3 2024 earnings summary

Executive summary

• Net revenue for 3Q24 reached R$1,915.9 million, down 10.4% year-over-year, mainly due to working capital optimization reducing client inventories.

• Sell-out growth accelerated to 11% in Q3 2024, driven by normalization in demand for flu, respiratory, pain, and fever products, with October sell-out up 13% and YTD growth at 9%.

• Free cash flow increased 23.2% year-over-year to R$551.8 million, reflecting lower investment in working capital and absence of prior year acquisition payments.

• Net income from continuing operations was R$370.5 million, down 25.9% year-over-year.

• Achieved a 10% increase in Dow Jones Sustainability Index score and revised board regulations.

Financial highlights

• Gross margin was 59.8% in 3Q24, down 3.5 p.p. year-over-year, with gross profit at R$1,145.7 million.

• EBITDA margin from continuing operations was 29.3%, down 8.0 p.p. year-over-year, with EBITDA at R$561.2 million.

• Marketing expenses increased 6%, selling expenses rose 5%, and G&A expenses grew 10% year-over-year.

• Free cash flow for 3Q24 was R$552 million, with operational cash generation at BRL 738 million.

• CapEx investments totaled BRL 107 million, focused on expanding production for the institutional market.

Outlook and guidance

• Working capital optimization expected to be 50% complete by end of Q4 2024, with most adjustments finished by early 2025 and fine-tuning through the year.

• Cash flow benefits from the strategy anticipated from Q1 2025, with strong long-term value generation expected.

• Revenue growth projected to resume from mid-2025 as inventory adjustments normalize.

• Working capital optimization aims to generate R$2.5 billion in cash by 2028 and R$7.5 billion over 10 years, with no impact on sell-out growth or planned investments.

• October 2024 preliminary sell-out growth reached 13%, with year-to-date growth at 9%.